Bragar Eagel & Squire, P.C. Launches Investigation into Agilon, Soleno, Avita, and Coty, Urging Investors to Reach Out to the Firm
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy AGL?
Source: Globenewswire
Agilon Health Investigation: Bragar Eagel & Squire, P.C. is investigating Agilon Health for potential violations of federal securities laws following the unexpected resignation of its CEO and the withdrawal of its earnings guidance, which led to a significant drop in share price.
Soleno Therapeutics Report: The law firm is also looking into Soleno Therapeutics after a report from Scorpion Capital criticized its product, Vykat XR, as overpriced and unsafe, resulting in a notable decline in the company's stock price.
AVITA Medical Claims Backlog: AVITA Medical is under investigation due to a reported backlog of unpaid claims for its Recell procedures, which negatively impacted its financial results and led to a sharp decrease in share price.
Coty's Financial Losses: Coty, Inc. is facing scrutiny after reporting an unexpected financial loss and disappointing guidance, attributed to broader market challenges, which caused its stock price to fall significantly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGL
Wall Street analysts forecast AGL stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 8.035
Low
0.88
Averages
0.88
High
0.88
Current: 8.035
Low
0.88
Averages
0.88
High
0.88
About AGL
agilon health, inc. is a healthcare company. The Company operates a Medicare-centric, capitated line of business. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing monthly payments to manage the total healthcare needs of its physician partners attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform supports the transition to a Total Care Model with technology, people, process and capital.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agilon Health Implements 1-for-25 Reverse Stock Split to Regain NYSE Compliance
- Reverse Stock Split: Agilon Health announced a 1-for-25 reverse stock split effective March 30, 2026, to comply with NYSE minimum bid price requirements, with trading on a split-adjusted basis starting March 31, aiming to lift its share price for continued listing compliance.
- Shareholder Approval: At a special meeting on March 17, shareholders approved the reverse split proposal ranging from 1-for-5 to 1-for-25, with the board opting for the 1-for-25 ratio, reflecting the company's responsiveness to shareholder input.
- Reduction in Outstanding Shares: Following the reverse split, Agilon Health's outstanding shares will decrease from approximately 415 million to about 16.6 million, which is expected to enhance the stock's marketability and liquidity, potentially attracting more investor interest.
- Value-Based Care Model: Agilon Health partners with physician groups and health systems to support a value-based care model for senior patients, providing technology, capital, and operational support, although the market remains cautious about its investment potential, it is still viewed as a stock with upside potential.
See More
Major U.S. Indices Decline as Inflation Exceeds Expectations
- Inflation Impact: On Wednesday, major U.S. indices closed lower after two days of gains, with the S&P 500 down 1.4%, the Nasdaq Composite down 1.5%, and the Dow Jones Industrial Average down 1.6%, reflecting investor concerns over hotter-than-expected wholesale inflation data.
- Micron Technology Earnings: Despite Micron Technology (MU) reporting adjusted earnings of $12.20 per share and revenue of $23.86 billion, both significantly exceeding Wall Street expectations with a 196.4% year-over-year increase, its shares fell approximately 3.5% in after-hours trading, indicating market caution regarding future performance.
- Five Below Sales Surge: Five Below (FIVE) saw its shares rise in after-hours trading following a 24.5% year-over-year sales increase to $1.73 billion in fiscal Q4, well above the 13.7% consensus estimate, with comparable sales jumping 15.3%, showcasing strong consumer demand and market performance.
- agilon health Stock Split: Agilon health (AGL) announced a 1-for-25 reverse stock split effective March 30, 2026, aimed at raising its share price above $1.00 to meet NYSE listing requirements, thereby improving stock liquidity and marketability to attract broader investor interest.
See More
Agilon Health Implements 1-for-25 Reverse Stock Split
- Reverse Stock Split Plan: Agilon Health (AGL) has announced a 1-for-25 reverse stock split effective March 30, 2026, aimed at raising its share price above $1.00 to meet NYSE listing requirements.
- Trading Adjustment Date: Post-split, shares will begin trading on a split-adjusted basis starting March 31, 2026, which is expected to enhance stock liquidity and market appeal.
- Increased Investor Interest: By elevating its stock price, Agilon Health aims to attract broader investor interest, thereby enhancing its market competitiveness and investment attractiveness.
- Financial Outlook: Agilon Health projects $5.5 billion in revenue for 2026, with a breakeven adjusted EBITDA amid transformation and disciplined contracting, indicating the company's potential in the value-based care sector.
See More
Halper Sadeh LLC Investigates Agilon Health Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact the firm to discuss their rights and options at no cost, aiming to ensure shareholders can enforce their rights within a limited timeframe.
- Corporate Governance Reform: The investigation focuses on whether certain officers and directors of Agilon Health, Inc. (NYSE:AGL) breached their fiduciary duties, allowing long-term shareholders to seek governance reforms and potential fund recovery.
- Enhancing Transparency: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, creating a more transparent, accountable, and effectively managed organization, ultimately enhancing shareholder value.
- Legal Support and Success Stories: Halper Sadeh LLC represents investors globally against securities fraud and corporate misconduct, with attorneys instrumental in implementing corporate reforms and recovering millions for defrauded investors.
See More
Agilon Health Shares Drop 7.6% Amid Rising Cost Concerns
- Cost Increase Forecast: Agilon Health projected a 7.5% rise in costs for 2026 during the Barclays Global Healthcare Conference, raising investor concerns about future profitability, which contributed to a 7.6% drop in share price.
- Cash Flow Goals: While the company aims for free cash flow break-even by 2027 and anticipates a $125 million benefit from contracting improvements, the immediate impact of rising costs has negatively affected investor sentiment.
- Market Volatility: Agilon Health's shares have experienced 82 moves greater than 5% over the past year, indicating that today's price movement is significant to the market but does not fundamentally alter perceptions of the business.
- Year-to-Date Performance: The stock has declined 11.8% since the beginning of the year, currently trading at $0.59 per share, which is 89.5% below its 52-week high of $5.68 from April 2025, reflecting a lack of investor confidence.
See More
Kuehn Law Investigates Agilon Health Executives' Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Agilon Health, Inc. breached their fiduciary duties to shareholders, with allegations of intentional misrepresentation in a federal securities lawsuit.
- Misleading Financial Guidance: The lawsuit claims that Agilon Health's guidance for 2025 was recklessly issued, as executives knew or should have known that the targets were unattainable, negatively impacting the company's future financial performance.
- Exaggerated Risk Management: It is also alleged that the immediate positive financial impact from strategic actions taken by Agilon to mitigate risks was materially overstated, leading to significant false or misleading statements about the company's business and operations during relevant periods.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased AGL stock prior to February 26, 2025, to contact their attorney immediately to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining the integrity and fairness of financial markets.
See More
Agilon Health Implements 1-for-25 Reverse Stock Split to Regain NYSE Compliance
- Reverse Stock Split: Agilon Health announced a 1-for-25 reverse stock split effective March 30, 2026, to comply with NYSE minimum bid price requirements, with trading on a split-adjusted basis starting March 31, aiming to lift its share price for continued listing compliance.
- Shareholder Approval: At a special meeting on March 17, shareholders approved the reverse split proposal ranging from 1-for-5 to 1-for-25, with the board opting for the 1-for-25 ratio, reflecting the company's responsiveness to shareholder input.
- Reduction in Outstanding Shares: Following the reverse split, Agilon Health's outstanding shares will decrease from approximately 415 million to about 16.6 million, which is expected to enhance the stock's marketability and liquidity, potentially attracting more investor interest.
- Value-Based Care Model: Agilon Health partners with physician groups and health systems to support a value-based care model for senior patients, providing technology, capital, and operational support, although the market remains cautious about its investment potential, it is still viewed as a stock with upside potential.
See More
Major U.S. Indices Decline as Inflation Exceeds Expectations
- Inflation Impact: On Wednesday, major U.S. indices closed lower after two days of gains, with the S&P 500 down 1.4%, the Nasdaq Composite down 1.5%, and the Dow Jones Industrial Average down 1.6%, reflecting investor concerns over hotter-than-expected wholesale inflation data.
- Micron Technology Earnings: Despite Micron Technology (MU) reporting adjusted earnings of $12.20 per share and revenue of $23.86 billion, both significantly exceeding Wall Street expectations with a 196.4% year-over-year increase, its shares fell approximately 3.5% in after-hours trading, indicating market caution regarding future performance.
- Five Below Sales Surge: Five Below (FIVE) saw its shares rise in after-hours trading following a 24.5% year-over-year sales increase to $1.73 billion in fiscal Q4, well above the 13.7% consensus estimate, with comparable sales jumping 15.3%, showcasing strong consumer demand and market performance.
- agilon health Stock Split: Agilon health (AGL) announced a 1-for-25 reverse stock split effective March 30, 2026, aimed at raising its share price above $1.00 to meet NYSE listing requirements, thereby improving stock liquidity and marketability to attract broader investor interest.
See More
Agilon Health Implements 1-for-25 Reverse Stock Split
- Reverse Stock Split Plan: Agilon Health (AGL) has announced a 1-for-25 reverse stock split effective March 30, 2026, aimed at raising its share price above $1.00 to meet NYSE listing requirements.
- Trading Adjustment Date: Post-split, shares will begin trading on a split-adjusted basis starting March 31, 2026, which is expected to enhance stock liquidity and market appeal.
- Increased Investor Interest: By elevating its stock price, Agilon Health aims to attract broader investor interest, thereby enhancing its market competitiveness and investment attractiveness.
- Financial Outlook: Agilon Health projects $5.5 billion in revenue for 2026, with a breakeven adjusted EBITDA amid transformation and disciplined contracting, indicating the company's potential in the value-based care sector.
See More
Halper Sadeh LLC Investigates Agilon Health Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact the firm to discuss their rights and options at no cost, aiming to ensure shareholders can enforce their rights within a limited timeframe.
- Corporate Governance Reform: The investigation focuses on whether certain officers and directors of Agilon Health, Inc. (NYSE:AGL) breached their fiduciary duties, allowing long-term shareholders to seek governance reforms and potential fund recovery.
- Enhancing Transparency: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, creating a more transparent, accountable, and effectively managed organization, ultimately enhancing shareholder value.
- Legal Support and Success Stories: Halper Sadeh LLC represents investors globally against securities fraud and corporate misconduct, with attorneys instrumental in implementing corporate reforms and recovering millions for defrauded investors.
See More
Agilon Health Shares Drop 7.6% Amid Rising Cost Concerns
- Cost Increase Forecast: Agilon Health projected a 7.5% rise in costs for 2026 during the Barclays Global Healthcare Conference, raising investor concerns about future profitability, which contributed to a 7.6% drop in share price.
- Cash Flow Goals: While the company aims for free cash flow break-even by 2027 and anticipates a $125 million benefit from contracting improvements, the immediate impact of rising costs has negatively affected investor sentiment.
- Market Volatility: Agilon Health's shares have experienced 82 moves greater than 5% over the past year, indicating that today's price movement is significant to the market but does not fundamentally alter perceptions of the business.
- Year-to-Date Performance: The stock has declined 11.8% since the beginning of the year, currently trading at $0.59 per share, which is 89.5% below its 52-week high of $5.68 from April 2025, reflecting a lack of investor confidence.
See More
Kuehn Law Investigates Agilon Health Executives' Fiduciary Duties
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Agilon Health, Inc. breached their fiduciary duties to shareholders, with allegations of intentional misrepresentation in a federal securities lawsuit.
- Misleading Financial Guidance: The lawsuit claims that Agilon Health's guidance for 2025 was recklessly issued, as executives knew or should have known that the targets were unattainable, negatively impacting the company's future financial performance.
- Exaggerated Risk Management: It is also alleged that the immediate positive financial impact from strategic actions taken by Agilon to mitigate risks was materially overstated, leading to significant false or misleading statements about the company's business and operations during relevant periods.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased AGL stock prior to February 26, 2025, to contact their attorney immediately to enforce their rights within a limited timeframe, emphasizing the importance of shareholder voices in maintaining the integrity and fairness of financial markets.
See More
